Study details
Enrolling now
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
AbbVie
NCT IDNCT06602479ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
408
Study length
about 2.6 years
Ages
18–70
Locations
16 sites in AL, CA, FL +7
What this study is about
This trial is testing a treatment called MEDI0618 compared to a placebo (inactive pill) in adults with episodic migraine. The goal is to see if MEDI0618 is safe and effective for treating this condition.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take MEDI0618
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Neurology